|
1
|
Mattiuzzi C and Lippi G: Current cancer
epidemiology. J Epidemiol Glob Health. 9:217–222. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nishimura T, Nakamura H, Végvári Á,
Marko-Varga G, Furuya N and Saji H: Current status of clinical
proteogenomics in lung cancer. Expert Rev Proteomics. 16:761–772.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bade BC and Dela Cruz CS: Lung Cancer
2020: Epidemiology, Etiology, and Prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reck M and Rabe KF: Precision diagnosis
and treatment for advanced non-small-cell lung cancer. N Engl J
Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kadara H, Scheet P, Wistuba II and Spira
AE: Early events in the molecular pathogenesis of lung cancer.
Cancer Prev Res (Phila). 9:518–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brosnan CA and Voinnet O: The long and the
short of noncoding RNAs. Curr Opin Cell Biol. 21:416–425. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Saeedi Borujeni MJ, Esfandiary E,
Baradaran A, Valiani A, Ghanadian M, Codoñer-Franch P, Basirat R,
Alonso-Iglesias E, Mirzaei H and Yazdani A: Molecular aspects of
pancreatic β-cell dysfunction: Oxidative stress, microRNA, and long
noncoding RNA. J Cell Physiol. 234:8411–8425. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ulitsky I and Bartel DP: lincRNAs:
Genomics, evolution, and mechanisms. Cell. 154:26–46. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iyer MK, Niknafs YS, Malik R, Singhal U,
Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et
al: The landscape of long noncoding RNAs in the human
transcriptome. Nat Genet. 47:199–208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Shen T, Ding X, Ma C, Cheng L,
Sheng L and Du X: lncRNA MRUL suppressed non-small cell lung cancer
cells proliferation and invasion by targeting miR-17-5p/SRSF2 axis.
BioMed Res Int. 2020:95678462020.PubMed/NCBI
|
|
14
|
Wang D, Zhang S, Zhao M and Chen F: LncRNA
MALAT1 accelerates non-small cell lung cancer progression via
regulating miR-185-5p/MDM4 axis. Cancer Med. 9:9138–9149. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang S, Wang T, Liu D and Kong H: LncRNA
MALAT1 aggravates the progression of non-small cell lung cancer by
stimulating the expression of COMMD8 via targeting miR-613. Cancer
Manag Res. 12:10735–10747. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye R, Tang R, Gan S, Li R, Cheng Y, Guo L,
Zeng C and Sun Y: New insights into long non-coding RNAs in
non-small cell lung cancer. Biomed Pharmacother. 131:1107752020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Q, Chen S, Zhao J, Zhou Y and Xu L:
MicroRNA-126: A new and promising player in lung cancer. Oncol
Lett. 21:352021.PubMed/NCBI
|
|
19
|
Ahn YH and Ko YH: Diagnostic and
therapeutic implications of microRNAs in non-small cell lung
cancer. Int J Mol Sci. 21:212020. View Article : Google Scholar
|
|
20
|
Hu C, Hui K and Jiang X: Effects of
microRNA regulation on antiangiogenic therapy resistance in
non-small cell lung cancer. Biomed Pharmacother. 131:1105572020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang WJ, Li HT, Yu JP, Han XP, Xu ZP, Li
YM, Jiao ZY and Liu HB: A competing endogenous RNA network reveals
novel potential lncRNA, miRNA, and mRNA biomarkers in the prognosis
of human colon adenocarcinoma. J Surg Res. 235:22–33. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Landeros N, Santoro PM, Carrasco-Avino G
and Corvalan AH: Competing endogenous RNA networks in the
epithelial to mesenchymal transition in diffuse-type of gastric
cancer. Cancers (Basel). 12:122020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu Y and Qian Z: Long non-coding RNAs
(lncRNAs) and microRNAs regulatory pathways in the tumorigenesis
and pathogenesis of glioma. Discov Med. 28:129–138. 2019.PubMed/NCBI
|
|
24
|
Li Y, Huang S, Li Y, Zhang W, He K, Zhao
M, Lin H, Li D, Zhang H, Zheng Z, et al: Decreased expression of
LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and
EMT in colorectal cancer cells. Tumour Biol. 37:14205–14215. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bu L, Tian Y, Wen H, Jia W and Yang S:
miR-195-5p exerts tumor-suppressive functions in human lung cancer
cells through targeting TrxR2. Acta Biochim Biophys Sin (Shanghai).
53:189–200. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Long Z and Wang Y: miR-195-5p Suppresses
lung cancer cell proliferation, migration, and invasion Via FOXK1.
Technol Cancer Res Treat. May 14–2020.(Epub ahead of print). doi:
10.1177/1533033820922587. View Article : Google Scholar
|
|
28
|
Luo J, Pan J, Jin Y, Li M and Chen M:
MiR-195-5p inhibits proliferation and induces apoptosis of
non-small cell lung cancer cells by targeting CEP55. Onco Targets
Ther. 12:11465–11474. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ricciuti B, Mencaroni C, Paglialunga L,
Paciullo F, Crinò L, Chiari R and Metro G: Long noncoding RNAs: New
insights into non-small cell lung cancer biology, diagnosis and
therapy. Med Oncol. 33:182016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhan Y, Zang H, Feng J, Lu J, Chen L and
Fan S: Long non-coding RNAs associated with non-small cell lung
cancer. Oncotarget. 8:69174–69184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen J, Wang R, Zhang K and Chen LB: Long
non-coding RNAs in non-small cell lung cancer as biomarkers and
therapeutic targets. J Cell Mol Med. 18:2425–2436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Samimi H, Sajjadi-Jazi SM, Seifirad S,
Atlasi R, Mahmoodzadeh H, Faghihi MA and Haghpanah V: Molecular
mechanisms of long non-coding RNAs in anaplastic thyroid cancer: A
systematic review. Cancer Cell Int. 20:3522020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qu J, Li M, Zhong W and Hu C: Competing
endogenous RNA in cancer: A new pattern of gene expression
regulation. Int J Clin Exp Med. 8:17110–17116. 2015.PubMed/NCBI
|
|
35
|
Wang X, Wang Y, Lan H and Li J: MiR-195
inhibits the growth and metastasis of NSCLC cells by targeting
IGF1R. Tumour Biol. 35:8765–8770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu B, Qu J, Xu F, Guo Y, Wang Y, Yu H and
Qian B: MiR-195 suppresses non-small cell lung cancer by targeting
CHEK1. Oncotarget. 6:9445–9456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu X, Zhang Y, Cavazos D, Ma X, Zhao Z, Du
L and Pertsemlidis A: miR-195 targets cyclin D3 and survivin to
modulate the tumorigenesis of non-small cell lung cancer. Cell
Death Dis. 9:1932018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X and Yang J: Role of non-coding
RNAs on the radiotherapy sensitivity and resistance of head and
neck cancer: From basic research to clinical application. Front
Cell Dev Biol. 8:6374352021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun W, Jiang C, Ji Y, Xiao C and Song H:
Long noncoding RNAs: New regulators of resistance to systemic
therapies for gastric cancer. BioMed Res Int. 2021:88532692021.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Ma X, Si H, Ma Z, Ma Y, Wang J and
Cao B: Role of long non-coding RNA H19 in therapy resistance of
digestive system cancers. Mol Med. 27:12021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ming H, Li B, Zhou L, Goel A and Huang C:
Long non-coding RNAs and cancer metastasis: Molecular basis and
therapeutic implications. Biochim Biophys Acta Rev Cancer.
1875:1885192021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen Y, Li Z, Chen X and Zhang S: Long
non-coding RNAs: From disease code to drug role. Acta Pharm Sin B.
11:340–354. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhou Y, Sun W, Qin Z, Guo S, Kang Y, Zeng
S and Yu L: LncRNA regulation: New frontiers in epigenetic
solutions to drug chemoresistance. Biochem Pharmacol. Sep
23–2020.(Epub ahead of print). doi: 10.1016/j.bcp.2020.114228.
View Article : Google Scholar
|
